Press Release, Helsinki, 2 September 2026 at 9 AM (EEST)
Nexstim Plc (”Nexstim” or ”Company”) announces having received an order for an NBS 6 system from a new customer in the United States. The customer is utilizing this NBS 6 to conduct research.
An advantage Nexstim offers compared to regular TMS systems on the market is its real-time E-field guidance, important for delivering accurate and repeatable stimulation to a specific area in the brain.
For TMS research, being able to control the stimulation location accurately and repeatably is extremely valuable. In order to understand, which TMS protocols and parameters work best, researchers need to be able to have confidence that key variables can be controlled while others are systematically adjusted. Consistent stimulation delivery is an important part of that process.
The user of an NBS 6 can be confident that whatever the location, angle or tilt of the TMS coil relative to the head, a stimulus with the calculated and displayed E-field will be reliably delivered to the targeted cortical location.
To date, Nexstim NBS 6 is the only FDA cleared and CE-marked navigated TMS system for pre-operative mapping of the motor and speech cortices of the brain, attesting to this unsurpassed accuracy and precision.
Mikko Karvinen, CEO of Nexstim, says:
"We are pleased to welcome this new customer to the growing global user community of Nexstim's navigated TMS technology. The order further strengthens Nexstim's presence among leading research institutions and demonstrates the continued interest in high-accuracy, high-precision navigated TMS for research applications."
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS System 6 is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com.